tiprankstipranks
Trending News
More News >
Xwell, Inc. (XWEL)
:XWEL

XWELL (XWEL) AI Stock Analysis

Compare
977 Followers

Top Page

XW

XWELL

(NASDAQ:XWEL)

Rating:44Neutral
Price Target:
$1.00
▲(2.04%Upside)
XWELL's overall score is primarily impacted by its poor financial performance and the risk of Nasdaq delisting. The technical analysis shows mixed signals, providing some short-term support but not enough to outweigh the fundamental challenges. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score.

XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)

XWELL Business Overview & Revenue Model

Company DescriptionXWELL Inc., a health and wellness services company, provides spa services at airports. It operates through XpresSpa, XpresTest, Treat, and HyperPointe brands. The company offers spa services, including massage, and nail and skin care, as well as spa and travel products; and retail products. It also operates wellness centers that provides COVID-19 screening and testing, and rapid testing services for other communicable diseases, such as influenza, COVID-19, RSV, Flu A&B, and seasonal flu vaccination services; and other medical diagnostic testing services. In addition, the company offers services through an integrated digital platform, and a relevant retail offering to the traveling public. As of December 31, 2021, it operated 52 spa and clinic locations in 24 airports in the United States, the Netherlands, and the United Arab Emirates. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL Inc. in October 2022. XWELL Inc. is headquartered in New York, New York.
How the Company Makes MoneyXWELL generates revenue through multiple streams primarily centered around its wellness centers and service offerings. The company earns money by providing spa and wellness services, which include massage therapy, skincare treatments, and other health-related services. Additionally, XWELL sells health and wellness products through its retail outlets, contributing to its income. The company may also engage in partnerships with other organizations within the health and wellness industry to expand its service offerings and reach a broader audience, further supporting its revenue generation.

XWELL Earnings Call Summary

Earnings Call Date:May 20, 2025
(Q3-2024)
|
% Change Since: 6.52%|
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.
Q3-2024 Updates
Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Strategic Expansion Plans
Planning to expand into several attractive markets in Florida, with up to 10 XWELL properties expected by mid-2025. Opening first Naples Wax location in November 2024.
Successful Cost Reduction
Reduced total operating expenses by approximately 35% for the 9-month period in 2024 compared to the same period in 2023.
Decrease in Operating Loss
Operating loss for Q3 2024 was $4.8 million, a significant improvement from an operating loss of $12.1 million in the prior year third quarter.
Solid Financial Position
No long-term debt with cash and cash equivalents at $4.4 million and $11.7 million in marketable securities.
Positive Customer Engagement
Customer traction and foot traffic at the new Philadelphia International Airport XpresSpa have been solid, with promising performance from tech-forward installations.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Legal Expenses Impact
General and administrative expenses were approximately $4.5 million, including over $2 million related to extraordinary legal expenses.
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.

XWELL Financial Statement Overview

Summary
XWELL is facing significant financial challenges with declining revenue, negative profit margins, and poor cash flows. The balance sheet shows negative equity, indicating financial distress and potential solvency issues.
Income Statement
35
Negative
The company's revenue has decreased significantly over the years, with a notable decline from 2021 to 2023. Gross profit margin improved slightly in 2023 compared to 2022, but remains weak at 26.3%. Net profit margin is negative, indicating consistent losses. EBIT and EBITDA margins are also negative, reflecting operational challenges despite some improvement in EBIT in 2024.
Balance Sheet
30
Negative
The company has a negative stockholders' equity in 2024, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is also negative, signaling potential solvency issues. Total assets have decreased significantly, impacting the company's financial stability.
Cash Flow
28
Negative
Operating cash flow is negative, indicating cash outflows from operations. Free cash flow is also negative, reflecting ongoing financial strain. Cash flow from financing activities has been inconsistent, with a significant drop in 2024. The operating cash flow to net income ratio suggests poor cash generation relative to net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue32.19M33.90M30.11M55.94M73.73M8.38M
Gross Profit7.57M8.92M3.68M12.05M32.43M-3.60M
EBITDA-12.76M-15.96M-15.75M-19.12M7.87M-19.54M
Net Income-19.06M-16.85M-27.74M-32.63M3.35M-92.23M
Balance Sheet
Total Assets24.83M25.35M38.99M70.43M127.27M103.13M
Cash, Cash Equivalents and Short-Term Investments10.97M11.80M23.05M42.19M105.51M89.80M
Total Debt10.03M10.77M11.09M14.11M13.82M15.38M
Total Liabilities21.40M17.61M18.02M22.48M27.33M22.76M
Stockholders Equity-5.23M-788.00K13.00M39.93M92.73M77.81M
Cash Flow
Free Cash Flow-13.43M-12.80M-18.45M-31.02M6.97M-29.36M
Operating Cash Flow-11.50M-11.01M-16.07M-24.19M15.64M-25.01M
Investing Cash Flow5.80M5.89M5.65M-34.84M-6.24M-4.35M
Financing Cash Flow5.10M1.36M8.00K-27.38M6.35M117.22M

XWELL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.98
Price Trends
50DMA
0.91
Positive
100DMA
0.93
Positive
200DMA
1.23
Negative
Market Momentum
MACD
0.02
Negative
RSI
55.18
Neutral
STOCH
64.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Positive. The current price of 0.98 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.91, and below the 200-day MA of 1.23, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.18 is Neutral, neither overbought nor oversold. The STOCH value of 64.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XWEL.

XWELL Risk Analysis

XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

XWELL Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
RGRGS
64
Neutral
$57.61M0.62548.07%-4.88%
MRMRM
63
Neutral
$10.67M7.7823.48%12.93%66.81%
MEMED
59
Neutral
$161.35M66.49-3.32%-39.47%-110.28%
52
Neutral
$11.02M-446.50%445.72%84.92%
52
Neutral
$7.59B0.30-61.86%2.27%16.72%1.10%
44
Neutral
$5.13M-797.66%1.33%35.82%
40
Underperform
$24.65M
-10.33%79.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XWEL
XWELL
0.98
-0.68
-40.96%
MED
Medifast
14.40
-4.23
-22.71%
RGS
Regis
23.09
2.25
10.80%
WGHTQ
WW International
0.31
-0.95
-75.40%
MRM
MEDIROM Healthcare Technologies
1.37
-2.49
-64.51%
TRNR
Interactive Strength Inc
7.78
-902.22
-99.15%

XWELL Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
XWELL Faces Nasdaq Delisting Risk Over Bid Price
Negative
May 19, 2025

On May 13, 2025, XWELL, Inc. received a notification from the Nasdaq Stock Market indicating that the company’s common stock did not meet the minimum bid price requirement of $1.00 per share over a 30-day period, which is necessary for continued listing on the Nasdaq Capital Market. XWELL has been given a compliance period until November 10, 2025, to meet this requirement by maintaining a minimum closing bid price of $1.00 for at least ten consecutive business days. If XWELL fails to comply within this period, they may qualify for an additional 180-day extension if they meet other listing standards and provide a plan to address the deficiency, potentially through a reverse stock split. The letter does not immediately affect the company’s stock listing, which remains active on Nasdaq.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025